Literature DB >> 30612100

UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines.

Ruth Dobson1,2, Pooja Dassan3,4, Megan Roberts5, Gavin Giovannoni2,6, Catherine Nelson-Piercy7,8, Peter A Brex9.   

Abstract

Multiple sclerosis (MS) is more common in women than men and is most commonly diagnosed in early adulthood; thus, many patients will not have completed their families at the time of diagnosis. There is increasing awareness of the importance of early treatment in preventing long-term disability in MS. Delaying treatment until women with MS have completed their families can lead to the development of irreversible disability in at least some cases. It is therefore important to discuss family planning and pregnancy proactively. However, to date there is limited evidence to inform such discussions. We set out to develop consensus guidelines for the treatment of MS in pregnancy to encourage and facilitate discussions in this important area. The guidelines draw on available evidence from drug-specific pregnancy registers and published literature and have been scored by a panel of experts from a variety of disciplines using modified Delphi criteria. They cover prepregnancy counselling, management during pregnancy, delivery and anaesthetic options, postpartum advice and specific advice regarding currently licensed disease-modifying drugs. As the complexity and range of available disease-modifying drugs increase, further data gathering via a UK-wide MS pregnancy register is recommended. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  disease modifying therapy; multiple sclerosis; pregnancy

Mesh:

Year:  2019        PMID: 30612100     DOI: 10.1136/practneurol-2018-002060

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  28 in total

1.  The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

Authors:  Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

2.  Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding.

Authors:  Sigal Kaplan; Mikhail Zeygarnik; Tal Stern
Journal:  Drug Saf       Date:  2022-03-16       Impact factor: 5.228

Review 3.  Pregnancy complicated by neurological and neurosurgical conditions - The evidence regarding mode of delivery.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2021-04-07

4.  Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.

Authors:  Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis
Journal:  Neurology       Date:  2021-04-20       Impact factor: 9.910

5.  Family Planning Decision Making in People With Multiple Sclerosis.

Authors:  Simona Bonavita; Luigi Lavorgna; Hilary Worton; Susan Russell; Dominic Jack
Journal:  Front Neurol       Date:  2021-04-28       Impact factor: 4.003

6.  Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset.

Authors:  Siew Mei Yap; Mary Dillon; Rachel K Crowley; Christopher McGuigan
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-06-18

7.  Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.

Authors:  Kerstin Hellwig; Yvonne Geissbuehler; Meritxell Sabidó; Catrinel Popescu; Alessandra Adamo; Joachim Klinger; Asher Ornoy; Peter Huppke
Journal:  J Neurol       Date:  2020-02-26       Impact factor: 4.849

Review 8.  Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.

Authors:  Isabella Laura Simone; Carla Tortorella; Alma Ghirelli
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

9.  The road to conception for women with multiple sclerosis.

Authors:  Dessa Sadovnick; Maria Criscuoli; Irene Yee; Robert Carruthers; Alice Schabas; Penelope Smyth
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-15

10.  Aggressive multiple sclerosis (2): Treatment.

Authors:  Georgina Arrambide; Ellen Iacobaeus; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Lou Brundin; Mar Tintore
Journal:  Mult Scler       Date:  2020-06-12       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.